Evidence-Based Glucose Management in Type 2 Diabetes
|
|
- Marsha Powers
- 6 years ago
- Views:
Transcription
1 Evidence-Based Glucose Management in Type 2 Diabetes James R. Gavin III, MD, PhD CEO and Chief Medical Officer Healing Our Village, Inc. Clinical Professor of Medicine Emory University School of Medicine Atlanta, Georgia
2 MANDATE FOR EVIDENCE-BASED APPROACH TO MANAGEMENT OF TYPE 2 DIABETES Focus on earlier diagnosis (A1C helpful?) Focus on earlier, more intensive interventions, including multiple drugs Focus on treat-to-goal, not treat-to-failure Focus on save the beta, lose the belly Focus on agents that avoid hypos & wt. gain Focus on greater individualization of therapy
3 International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes Advantages of A1c in diagnosis Better standardized than glucose Better index of glycemic exposure Less biologic variability Less pre-analytic instability No need for fasting Less affected by stress or illness Currently used to guide tx THE INTERNATIONAL EXPERT COMMITTEE. Diabetes Care 2009;32:1327
4 International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes 6.5 THE INTERNATIONAL EXPERT COMMITTEE. Diabetes Care 2009;32:1327
5 Greater cost of individual test Limited availability of A1C testing in certain regions of the developing world Variable correlation between A1C and average glucose, especially in certain minority groups Incomplete overlap with FPG and 2 hour PCG Inaccurate in patients with anemia and hemoglobinopathies. Tan"
6 If we accomplish earlier diagnosis, is there some advantage to the achievement of early, intensive glucose control? Does the legacy effect exist in diabetes?
7 EDIC Results: In Diabetes Treatment, Start with Glucose Rx (Nephropathy A1c Levels) HbA1c (%) N=1349. Writing Team for the DCCT/ EDIC Research Group. JAMA. 2003;290:
8 DCCT EDIC: Early Intensive Therapy Reduced Risk of CVD Events in Type 1 Diabetes Cumulative Incidence Any Predefined CVD Outcome 42% Risk Reduction (95% CI, 9%-63%; P = 0.02) Conventional Treatment Intensive Treatment 57% Risk Reduction (95% CI, 12%-79%; P = 0.02) Nonfatal MI, Stroke, or Death From CVD Years Since Entry Years Since Entry Predefined CVD outcome = nonfatal MI or stroke; death judged to be due to CVD; subclinical MI; angina, confirmed by ischemic changes on exercise tolerance testing or by clinically significant obstruction on coronary angiography; or the need for revascularization with angioplasty or coronary artery bypass. Nathan DM et al for the DCCT/EDIC Study Research Group. N Engl J Med. 2005;353:
9 Legacy Effect of Earlier Glucose Control After Median 8.5 Years Post-trial Follow-up in UKPDS Aggregate Endpoint Any diabetes-related endpoint RRR: 12% 9% P: Microvascular disease RRR: 25% 24% P: Myocardial infarction RRR: 16% 15% P: All-cause mortality RRR: 6% 13% P: RRR = Relative Risk Reduction, P = Log Rank Holman RR et al. N Engl J Med. 2008;359:
10 The Importance of Getting to Goal: Reduction in Long-term Diabetes Complications Correlation between a 1% A1C decrease and reduced risk of complications 43% 37% 19% 16% 14% 12% Heart failure Cataract extraction Myocardial infarction Stroke Microvascular disease Cardiovascular complications Lower extremity amputation or fatal peripheral vascular disease Data from United Kingdom Prospective Diabetes Study (UKPDS). Stratton IM et al. BMJ. 2000;321:
11 Earlier Use of Combination Therapy May Improve Treating to Target Compared With Conventional Therapy Diet and exercise Traditional stepwise approach--- Early combination approach--- OAD monotherapy OAD uptitration OAD combination OAD + basal insulin OAD + multiple daily insulin injections A1C (%) Mean A1C of patients Time Duration of diabetes Adapted from Del Prato S et al. Int J Clin Pract. 2005;59: and Campbell IW. Br J Cardiol. 2000;7:
12 Mean Change from Baseline FPG (mg/dl) *P=0.001 N=632 Weeks DeFronzo RA et al. N Engl J Med. 1995;333:
13 β-cell Function Declines as DM Progresses: Can Treatment Fix This Problem? 100 β-cell function declines over time β-cell function (%) IGT Postprandial hyperglycemia Diagnosis Type 2 Phase 1 Years from diagnosis β-cell decline exceeds 50% by time of diagnosis Type 2 Phase 2 Insulin initiation Type 2 Phase Lebovitz HE. Diabetes Rev. 1999;7:
14 ADOPT: rosiglitazone reduces the rate of loss of β-cell function 0 Glibenclamide Metformin Rosiglitazone 2 Annual rate of β-cell function loss (%, HOMA analysis) * 10 Error bars = 95% CI *P < vs rosiglitazone P = 0.02 vs rosiglitazone Rate of decline from 6 months to 5 years Adapted from Kahn SE, et al. N Engl J Med 2006; 355:
15 Early initiation of insulin therapy restored beta-cell function Beta-cell function 1,400 1,200 1, Insulin in continuous subcutaneous infusion (CSII) Insulin in multi-injections (MDI) p < OAD p = Before therapy After therapy At 1 year Newly-diagnosed (382) T2DM patients treated until Euglycaemia was achieved, then followed on diet and exercise Beta-cell function assessed by acute insulin response (first-phase β-cell insulin secretion) Weng et al. Lancet. 2008;371:
16 GLP-1 Receptor Agonists Exhibit Early Favorable Effects on β-cell Function 3-year treatment with EXN BID vs. insulin glargine with a 4-week w/o period EXN, n = 16; IG, n = 20 A1C Reduction 1 st Phase Insulin Secretion a Insulin Sensitivity a EXN BID IG P -0.7% -0.5% = = % - EXN =. 006 IG =.647 a Measured as C-peptide secretion with euglycemic/ hyperinsulinemic and arginine-stimulated hyperglycemia clamp and calculated disposition index (DI). b P<.0001; c P<.0001 vs. LIRA 1.2 mg; d once daily. Meta-analysis of 6 LIRA trials 26-week treatment LIRA 1.8, n = 1363; LIRA 1.2, n = 896; RSG, n = 231; GLIM, n = 490; PBO, n = 524; EXN, n = 231 LIRA 1.2 mg d LIRA 1.8 mg d Δ HOMA-B (%) ΔP/IR EXN BID 5.7 b PBO 7.4 b,c 0.03 b,c Bunck M, et al. Diabetes. 2010; 59(suppl1): 728-P; Matthews D, et al. Diabetes. 2010; 59(suppl1): 1513-P.
17 NEW DIRECTIONS IN APPROACH TO MANAGEMENT OF TYPE 2 DIABETES Focus on earlier diagnosis (A1C helpful?) Focus on earlier, more intensive interventions, including multiple drugs Focus on treat-to-goal, not treat-to-failure Shift to save the beta, lose the belly Focus on agents that avoid hypos & wt. gain Focus on greater individualization of therapy
18 WE NEED HELP WITH THE OBESITY EPIDEMIC! Diabetes Obesity Hypertension Dyslipidemia 10/16/10 SYDNEY Study Group NeuroDiab 2001, Aberdeen 18
19 Exenatide Twice Daily: Weight Control in Individuals Without Diabetes Obese individuals without diabetes: Placebo/exenatide + lifestyle regimen N = 152 intent-totreat population Average BMI at baseline = 39.6 kg/m 2 77% of exenatide vs 56% of placebo patients with IGT or IFG normalized during the study P <.001 Rosenstock J, et al. Diabetes Care Mar 23. [Epub ahead of print].
20 Liraglutide Reduces Weight and Reverses Prediabetes a in Nondiabetic Adults c b Liraglutide 1.8 mg Liraglutide 1.2 mg Orlistat PBO Median Change in β-cell Function in 20 Weeks PBO -21% Orlistat -17% Liraglutide 1.2 mg +21.4% Liraglutide 1.8 mg +27.5% a Prediabetes = impaired glucose tolerance and impaired fasting glucose, measured by OGTT at randomization and week 20; n = 98 PBO; n = 95 LIRA 1.2; n = 90 LIRA 1.8; b P <.0001 vs PBO or Orlistat; n = 95 Orlistat c P =.008 vs Orlistat. Astrup A, et al. Lancet. 2009;374:
21 Improvement in CV Risk Factors With Exenatide Treatment (3.5 yr f/u) CV Risk Factor 3.5-Year Completer Population (N = 151) Baseline (mean ± SEM) TG (mg/dl) ± 11.6 Change From Baseline (mean ± SEM) ± Mean % Change 95% CI P value -68.3, TC (mg/dl) ± ± , HDL-C (mg/dl) 38.6 ± ± , 9.7 < LDL-C (mg/dl) ± ± , -6.1 < Systolic BP (mmhg) ± ± , Diastolic BP (mmhg) 79.2 ± ± , -1.7 < Klonoff DC, et al. Curr Med Res Opin. 2008;24:
22 GIVEN THE BENEFITS OF INCRETIN ACTIONS IN T2DM---IS IT TIME TO RETIRE THE MORE TRADITIONAL SECRETAGOGUES, OR AT LEAST CONSIDER IT? The secretagogues (i.e. SFUs) have poor durability of effectiveness in glucose-lowering in T2DM The secretagogues show no ability to preserve beta cell function or promote neogenesis The secretagogues do not predictably behave in a glucose-dependent fashion, promoting hypoglycemia Secretagogues have been associated with toxic effects on ischemic myocardium (there may in fact be other risks!) There are no documented beneficial effects of secretagogues on cardiovascular risk factors
23 Mean HbA1C (%) Over Time --- a further indictment of sulfonylureas? Background Metformin Background Sulfonylurea HbA1C (%) HbA1C (%) Sulfonylurea: n=1084 Metformin: n= P< P< Rosiglitazone: n= Rosiglitazone: n= Time (years) Model-adjusted mean (%, SE) N= Time (years) Home PD, Pocock SJ, Beck- Nielsen H, et al; RECORD Study Team. Lancet. 2009;373(9681):
24 Incretin-Based Therapies as the New Secretagogues: Effects on β-cell Function Sulfonylureas (SU) do not have pleiotropic effects on β cells and may actually worsen β- cell function Preclinical animal studies of GLP-1 agonists and DPP-4 inhibitors have demonstrated β-cell proliferation and preservation Clinical studies of GLP-1 agonists and DPP-4 inhibitors have demonstrated improved indices of β-cell function Actual preservation of such function in humans over time remains to be established DPP-4=dipeptidyl peptidase-4; GLP-1=glucagon-like peptide-1. Drab SR. Pharmacotherapy. 2009;29(12 Pt 2):43S-54S; Kim W, Egan JM. Pharmacol Rev. 2008;60: ; Riche DM et al. Am J Med Sci. 2009;337:
25 Once DM is Treated---How Tight Should Glucose Control Be? Epidemiologic studies have shown a relationship between A1C levels and CV events in patients with type 2 diabetes Lessons learned from three randomized controlled trials ACCORD (average age 62.2 years, 27% Hispanic or African-American) ADVANCE (average age 66 years, 37% Asian) VADT (average age 60.5 years, 38% Hispanic, African- American or Native American) Average age in the UKPDS was 53 years
26 HOW TIGHT SHOULD GLUCOSE CONTROL BE TO REDUCE CVD? Outcome ACCORD ADVANCE VADT HbA 1c (%) (Intensive vs. Standard) Nonfatal MI (%) (Intensive vs. Standard) CV Death (%) (Intensive vs. Standard) 6.4 vs vs vs vs. 4.6% 2.7 vs vs vs vs vs.1.7 indicates statistical significance Lesson: Goal of HbA1c <7.0% may be appropriate for those with advanced age, if it can be done safely; use individualized, patient-centered approach Loosen targets for those with advanced cardiovascular disease
27 ADA/ACC/AHA Recommended A1C Goals: Putting CV Trials in Perspective Target Pa)ent Characteris)cs <7% General diabeic populaion Lower than <7% Less stringent than <7% Short duraion of diabetes Long life expectancy No significant CVD No significant hypoglycemia or other adverse effects of treatment History of severe hypoglycemia Limited life expectancy Advanced microvascular or macrovascular complicaions Extensive comorbid condiions Longstanding diabetes in which the general goal has been difficult to a[ain despite DSME, appropriate glucose monitoring, and effecive doses of muliple glucose- lowering agents including insulin Skyler JS, et al. Diabetes Care. 2009;32(1):
28 Major Conclusions Concerning Use of Algorithms and Guidelines for Control Multidisciplinary care should be initiated at diagnosis and throughout care Metformin is cornerstone of therapy Match drug the needs of the individual patient Frequent medication adjustments required---no inertia! Use all of the available treatments when required to achieve goals, including insulin, achieving synergy
29 Informed, Empowered Patient: An Essential Element of Good Chronic Illness Care Informed, empowered patients What characterizes an informed, empowered patient?
30 MANDATE FOR EVIDENCE-BASED APPROACH TO MANAGEMENT OF TYPE 2 DIABETES Focus on earlier diagnosis (A1C helpful?) Focus on earlier, more intensive interventions, including multiple drugs Focus on treat-to-goal, not treat-to-failure Focus on save the beta, lose the belly Focus on agents that avoid hypos & wt. gain Focus on greater individualization of therapy
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationHanyang University Guri Hospital Chang Beom Lee
Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationGlucose and CV disease
Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationA Fork in the Road: Navigating Through New Terrain
A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More information효과적인경구혈당강하제의조합은? 대한당뇨병학회제 17 차연수강좌 ( ) 가천의대길병원내분비대사내과
효과적인경구혈당강하제의조합은? 대한당뇨병학회제 17 차연수강좌 (2011.10.30.) 가천의대길병원내분비대사내과 박이병 내용 배경 경구혈당강하제의병합이왜필요한가? (WHY?) 경구혈당강하제의병합은언제시작하나? (WHEN?) 경구혈당강하제의병합은어떻게하는것이좋은가?(HOW) 맺음말 배경 : drugs for treating diabetes In 1995 :
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationSlide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now
Slide 1 A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for
More informationMANAGEMENT OF DIABETES IN MINORITIES: A MATTER OF URGENCY
MANAGEMENT OF DIABETES IN MINORITIES: A MATTER OF URGENCY James R. Gavin III, MD, PhD CEO & Chief Medical Officer Healing Our Village, Inc. Clinical Professor of Medicine Emory University School of Medicine
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationCONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE. AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY. sul Paziente ad alto rischio CV*
CONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY sul Paziente ad alto rischio CV* Does reducing hyperglycemia protect against cardiovascular risk?
More informationManagement of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationManagement of Diabetes Mellitus: A Primary Care Perspective
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationEvolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk
Evolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk Harvard/Joslin Primary Care Congress for Cardiometabolic Health 2013 Richard S. Beaser, MD Medical Executive
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationWhat s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016
What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationGlucose Control: Does it lower CV risk?
Glucose Control: Does it lower CV risk? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationManagement of Diabetes
Management of Diabetes Mellitus: Which Drugs for Which Patients? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu Disclosure No relevant financial relationships
More informationDPP-4 inhibitor. The new class drug for Diabetes
DPP-4 inhibitor The new class drug for Diabetes 1 Cause of Death in Korea 1 st ; Neoplasm 2 nd ; Cardiovascular Disease 3 rd ; Cerebrovascular Disease Diabetes 2 Incidence of Fatal or Nonfatal MI During
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationCURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2013 BMI
More informationMetabolic Karma. - Essential Solution in Type2 DM - Eun Gyoung Hong, M.D., Ph.D
2014 ICDM Breakfast Symposium. Oct 18, 2014 Grand Hilton, Seoul Metabolic Karma - Essential Solution in Type2 DM - Eun Gyoung Hong, M.D., Ph.D Department of Endocrinology and Metabolism, Hallym University
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationVipul Lakhani, MD Oregon Medical Group Endocrinology
Vipul Lakhani, MD Oregon Medical Group Endocrinology Disclosures None Objectives Be able to diagnose diabetes and assess control Be able to identify appropriate classes of medications for diabetes treatment
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More information1/28/2014. The Metabolic Syndrome: Early History. Insulin Resistance: Early Diagnosis and Treatment to Prevent Cardiovascular Disease
: Early Diagnosis and Treatment to Prevent Cardiovascular Disease Henry N. Ginsberg, M.D. Irving Professor of Medicine Columbia University College of Physicans and Surgeons The Metabolic Syndrome: Early
More informationCURRENT ISSUES IN DIABETES MANAGEMENT
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2011 BMI
More informationBeyond A1C. Non-glycemic Effects of GLP-1 Receptor Agonists. Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows
Beyond A1C Non-glycemic Effects of GLP-1 Receptor Agonists Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows Disclosures No conflicts of interest. Learning Objectives 1. Understand the physiological
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Noninsulin Treatment of Diabetes: What the PCP Needs to Know
Non Insulin Treatment of Type 2 Diabetes: What the PCP Needs to Know Martin J. Abrahamson, MD Senior Vice President for Medical Affairs Joslin Diabetes Center Associate Professor of Medicine Harvard Medical
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationCURRENT ISSUES IN DIABETES MANAGEMENT
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact DIABETES
More informationCV Risk Management in Diabetes Mellitus
CV Risk Management in Diabetes Mellitus J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine University of California, San Francisco Mr. B 40 y/o Latino male c/o fatigue,
More informationAddressing Addressing Challenges in Type 2 Challenges in Type 2 Diabetes Diabetes Speaker:
Addressing Challenges in Type 2 Diabetes Geneva Briggs, PharmD,, BCPS Addressing Challenges in Type 2 Diabetes Speaker: Dr. Geneva Clark Briggs, a board-certified Pharmacotherapy Specialist, received her
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationIntensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?
Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationStandards of Medical Care in Diabetes 2016
Standards of Medical Care in Diabetes 2016 Care Delivery Systems 33-49% of patients still do not meet targets for A1C, blood pressure, or lipids. 14% meet targets for all A1C, BP, lipids, and nonsmoking
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationClinical Overview of Combination Therapy with Sitagliptin and Metformin
Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationADVANCE Endpoints. Primary outcome. Secondary outcomes
ADVANCE Trial-NEJM 11,140 type 2 patients with h/o microvascular or macrovascular disease or 1 vascular disease risk factor Control A1c to 6.5% vs standard tx Intensive arm received gliclazide XL 30 to
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationOptimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes
Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationMicrovascular Complications in Diabetes:
Microvascular Complications in Diabetes: Perspectives on Glycemic Control to Prevent Microvascular Complications Discussion Outline: Glycemia and Microvascular Compliations Clinical Trials - A Brief History
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Choosing the Right Agent for your Patient with diabetes: Individualizing type 2 diabetes management in light of the expanding therapies
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationMANAGING DIABETES IN 2016 WHAT TO ADD, WHEN AND WHY?
MANAGING DIABETES IN 2016 WHAT TO ADD, WHEN AND WHY? Faculty: Maria Wolfs MD, MHSc, FRCPC Assistant Professor, University of Toronto Staff Endocrinologist, St. Michael's Hospital Relationships with commercial
More informationSulfoniluree e glinidi: pro e contro
Sulfoniluree e glinidi: pro e contro Giorgio Sesti Università Magna Graecia di Catanzaro ITALY T2DM anti-hyperglycaemic therapy: general recommendations Diabetes Care 35:1364-1379, 2012; Diabetologia 55:1577-1596,
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationManaging Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University
Managing Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University Objectives: By the end of this session, you will be able to: Identify
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More information